Biogen (BIIB) Assets Average (2009 - 2026)
Biogen (BIIB) posted quarterly Assets Average of $30.8 billion for Q2 2026, up 9.24% year-over-year from $28.2 billion in Q2 2025, and up 4.49% quarter-over-quarter from $29.5 billion in Q1 2026.
Biogen (BIIB) Assets Average (2009 - 2026) Analysis & Trends
Biogen's Assets Average history runs 18 years deep, the most recent figure standing at $30.8 billion for Q2 2026.
- In Q2 2026, Assets Average rose 9.24% year-over-year to $30.8 billion; the TTM figure through Jun 2026 stood at $30.8 billion (up 9.24% YoY), while the FY2025 annual figure was $28.7 billion, up 4.73% from the prior year.
- Assets Average for Q2 2026 stood at $30.8 billion, up from $29.5 billion in the prior quarter.
- The five-year high for Assets Average was $30.8 billion in Q2 2026, with the low at $23.7 billion in Q1 2022.
- The 5-year median for Assets Average is $27.1 billion (2023), against an average of $27.0 billion.
- The sharpest annual moves came in 2022 and 2023: Assets Average dropped 2.03% in 2022, then increased 11.39% in 2023.
- Biogen's Assets Average stood at $24.7 billion in 2022, then advanced by 11.39% to $27.5 billion in 2023, then rose by 2.41% to $28.2 billion in 2024, then gained by 4.05% to $29.3 billion in 2025, then climbed by 4.98% to $30.8 billion in 2026.
- Business Quant data shows BIIB's Assets Average at $30.8 billion in Q2 2026, $29.5 billion in Q1 2026, and $29.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.37 Bn | 632.61 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 469.65 Bn | 463.08 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 376.13 Bn | 368.99 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 303.28 Bn | 295.59 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 258.06 Bn | 253.16 Bn | 12.86 Bn | 114.92 Bn |
| 6 | Amgen | 236.35 Bn | 222.36 Bn | 7.24 Bn | 94.07 Bn |
| 7 | Gilead Sciences | 182.15 Bn | 178.97 Bn | 6.22 Bn | 52.82 Bn |
| 8 | Pfizer | 159.57 Bn | 147.87 Bn | 10.94 Bn | 204.57 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 83.80 Bn |
| 10 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 30.78 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.78 Bn |
| Mar 31, 2026 | 29.46 Bn |
| Dec 31, 2025 | 29.32 Bn |
| Sep 30, 2025 | 28.77 Bn |
| Jun 30, 2025 | 28.18 Bn |
| Mar 31, 2025 | 28.04 Bn |
| Dec 31, 2024 | 28.18 Bn |
| Sep 30, 2024 | 27.56 Bn |
| Jun 30, 2024 | 26.69 Bn |
| Mar 31, 2024 | 26.71 Bn |
| Dec 31, 2023 | 27.52 Bn |
| Sep 30, 2023 | 26.68 Bn |
| Jun 30, 2023 | 24.88 Bn |
| Mar 31, 2023 | 24.58 Bn |
| Dec 31, 2022 | 24.70 Bn |
| Sep 30, 2022 | 24.97 Bn |
| Jun 30, 2022 | 24.35 Bn |
| Mar 31, 2022 | 23.75 Bn |
| Dec 31, 2021 | 23.84 Bn |
| Sep 30, 2021 | 24.14 Bn |